EP1107807B1 - Utilisation de citrate dans une solution de controle de catheter - Google Patents

Utilisation de citrate dans une solution de controle de catheter Download PDF

Info

Publication number
EP1107807B1
EP1107807B1 EP99943881A EP99943881A EP1107807B1 EP 1107807 B1 EP1107807 B1 EP 1107807B1 EP 99943881 A EP99943881 A EP 99943881A EP 99943881 A EP99943881 A EP 99943881A EP 1107807 B1 EP1107807 B1 EP 1107807B1
Authority
EP
European Patent Office
Prior art keywords
catheter
lock solution
catheters
citrate
lock
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
EP99943881A
Other languages
German (de)
English (en)
Other versions
EP1107807A4 (fr
EP1107807A1 (fr
Inventor
Stephen R. Ash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ash Access Technology Inc
Original Assignee
Ash Access Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22265079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1107807(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ash Access Technology Inc filed Critical Ash Access Technology Inc
Publication of EP1107807A1 publication Critical patent/EP1107807A1/fr
Publication of EP1107807A4 publication Critical patent/EP1107807A4/fr
Application granted granted Critical
Publication of EP1107807B1 publication Critical patent/EP1107807B1/fr
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0017—Catheters; Hollow probes specially adapted for long-term hygiene care, e.g. urethral or indwelling catheters to prevent infections
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M2005/1401—Functional features
    • A61M2005/1403—Flushing or purging

Definitions

  • This invention generally relates to the use of lock solutions for infusion into an indwelling intravascular catheter to inhibit infection related to the presence of the catheter.
  • catheters are used with increasing frequency to treat patients requiring a variety of medical procedures.
  • the catheters offer many advantages for patients; for example, catheters provide ready access without repeated injections for administration of large volumes of fluids, nutrients, medications and withdrawal of blood.
  • the catheters can either be acute or temporary for short-term use or chronic for long-term treatment. They are commonly inserted into central veins (such as the vena cava) from peripheral vein sites. Great care must be taken in the placement and use of a chronic catheter to prevent infection of the patient at the site of access or within the vascular system.
  • Chronic venous catheters usually contain a DACRON® cuff attached to the catheter and placed under the skin, which promotes ingrowth of fibrous tissue, fixes the catheter in position, and prevents bacterial migration around the catheter.
  • Catheters can be used for infusion of fluids, such as, for example, drugs, electrolytes or fluids used in chemotherapy, or for the removal of blood on an intermittent basis.
  • fluids such as, for example, drugs, electrolytes or fluids used in chemotherapy
  • the catheters are usually used for infusion of large volumes of fluids.
  • chemotherapy catheters are used for infusion of drugs on an intermittent basis, ranging from daily to weekly.
  • dual-lumen catheters are used--usually three times per week; one lumen allows removal of blood, while the other lumen allows blood to return.
  • catheters, especially chronic catheters have drawbacks. They can become occluded by a thrombus, and even if extreme care is taken, the catheters can increase a patient's risk of infection.
  • the catheters are usually filled with a lock solution that comprises a concentrated solution of the commonly used anticoagulant, heparin (up to 10,000 units of heparin per catheter lumen).
  • heparin up to 10,000 units of heparin per catheter lumen.
  • the heparin lock solution is injected into each lumen immediately after each use, and preferably left in the catheter until the catheter is accessed again.
  • the heparin lock solution must be withdrawn from the catheter before the next use because infusing this amount of heparin in a patient might result in excessive bleeding.
  • the catheter can become occluded between uses from coagulation of blood in the catheter.
  • Blood may be found in the catheter because, for example, an inadequate volume of heparin was infused within the catheter lumen, the heparin diffused from the lumen, or residual blood remains in the lumen. This often results in formation of a thrombus with concomitant loss of flow through the lumen.
  • the occluded catheters frequently are removed and/or replaced.
  • catheters are inserted into veins or arteries, they bypass the protective dermis layer, and provide direct access to a patient's blood stream. This can cause the inadvertent transfer of infectious agents into the vein or artery at the location of the catheter.
  • the foreign surfaces of catheters can create a smooth surface at which bacteria can grow, and at which the white cells are unable to surround or "phagocytize" the bacteria.
  • Heparin has no anti-bacterial properties and, in fact, may help to promote growth of bacteria within the "biofilm” layer of protein on the catheter surfaces (protamine has the opposite effect).
  • the "biofilm” proteins on the catheter surfaces can protect bacteria from antibiotics and white cells.
  • heparin induces the loss of platelets and, paradoxically, can induce clotting in some patients (the "white clot” syndrome).
  • catheters particularly venous catheters, are frequently accessed with syringes, or uncapped and directly connected to IV lines, they have a propensity to become contaminated. If there is bacteremia (bacteria in blood), then the catheter surfaces within the vein or artery can become seeded with bacteria. In either case, the patient can develop septicemia (infection in the blood) and become seriously ill. Often these patients must be hospitalized and given intravenous antibiotics. In spite of this care, patients often remain seriously ill until the infected catheter is removed.
  • Hesse A et al (Urologia Internationalis 1989 Switzerland, Vo. 44, No. 6, 1989, pages 364-369) discloses testing of a citrate lock solution with urinary tract models (including artificial urine) in order to avoid encrustation and infection. There is a similar disclosure in a further publication from Hesse A et al (British Journal of Urology. England Oct 1992, Vol. 70, No. 4, October 1992 (1992-10), pages 429-434).
  • US-A-5 688 516 discloses use of a solution of an antibiotic (e.g. tetracycline) and (zinc) citrate for the prevention of infection occurring with indwelling catheters.
  • the present invention relates to catheter lock solutions for infusion into the lumen of an in-dwelling intravascular catheter.
  • the catheter lock solution can include a viscosifying agent such as polyethylene glycol, glycerin, polyclycerin or mixtures thereof.
  • the lock solution may be prepared to have a pH level lower than 6.5, more preferably between 4.5 and 6.5.
  • the lock solution has a density and a viscosity sufficient to maintain the lock solution in the lumen for a desired amount of time.
  • the lock solution may have a viscosity of from 1.5 mPa to 4.0 mPa.
  • a sufficient amount of the lock solution may be infused into the lumen of the catheter to fill, in percent by volume, between 80% and 100% of the internal volume of the catheter.
  • a bactericidal component including greater than 50% by weight, based on the weight of the bactericidal component, of a citrate salt for the manufacture of a medicament in the form of a pharmaceutically acceptable lock solution for infusion into the lumen of an in-dwelling intravascular catheter that has been surgically implanted into an animal having an infection or substantial risk of infection related to the presence of the catheter.
  • the lock solution employed in the second aspect of the invention may comprise the citrate salt in a concentration range, in weight percent, of between 1.5% and 50%, more preferably between 10% and 50%.
  • the lock solution enhances the patency of the catheter and exhibits anti-coagulation and antibiotic activity.
  • the lock solution provides particular advantages by increasing the longevity of catheters, reducing incidence of catheter occlusion, and reducing incidence of sepsis or bacterial infection in the patient.
  • the lock solution used in the present invention can be used with or without other anticoagulant agents and/or other antibacterial agents.
  • certain lock solutions for use in the present invention can be infused into the patient from the catheter in preparation for a subsequent use of the catheter without the necessity of withdrawing the lock solution from the catheter before infusion of additional fluids or medications.
  • the catheters for use with the present invention typically can either be acute (temporary) or chronic (long-term) catheters surgically implanted in the animal.
  • the catheters usually are inserted into a vein or artery.
  • the catheters are typically used in varying intervals to administer fluids, nutrients, and medications into the body.
  • the catheters also can be used to withdraw body fluids, such as blood, for hemodialysis treatment. When not in use, the catheter remains in its intravascular position until subsequent treatment is preferred
  • the catheters used in accordance with this invention include known and commonly used catheters and are readily available from a variety of commercial sources.
  • the catheters may vary in configuration and size.
  • One type of catheter commonly used in accordance with this invention is a tunneled catheter that includes a cuff for ingrowth of tissue to anchor the catheter.
  • catheters that may be used include, but are not restricted to, an ASH SPLITCATH® by Ash Medical of West Lafayette, Indiana; TESIO® and ASH® CATHETERS by Medcomp of Harleysville, Pennsylvania; PERM CATH® by Quinton Instrument Company of Seattle, Washington; HICKMAN and VAS CATH® by Bard, Inc. of Salt Lake City, Utah.
  • Catheters containing totally subcutaneous ports are also useful in the present invention; examples include LIFESITE® by Vasca of Topsfield, Maine, and DIALOCK® by Biolink, Inc. of Boston, Massachusetts.
  • FIG. 1 depicts one example of a catheter 10 for use with this invention.
  • Catheter 10 is a dual lumen catheter and includes an outer sheath 12 having a cuff 38 and first and second lumens 14 and 16, respectively.
  • Lumens 14 and 16 extend from distal tip 18 through sheath 12 and exit from sheath 12 at connection 36.
  • Each of lumens 14 and 16 include releasable clamps 20 and 22, respectively.
  • Each of lumens 14 and 16 terminate in a threaded end 24 and 26, which can be threadedly attached to protective end caps 28 and 30, respectively.
  • Fluids including a lock solution can be infused or withdrawn from each lumen 14 and 16 by inserting needle 32 of a syringe 34 through protective end caps 28 and/or 30 after protective end caps 28 and/or 30 have been sterilized by cleaning successively, for example with betadine and alcohol.
  • one or both protective end caps 28 and 30 can be removed and threaded ends 24 and 26 can be threadedly attached via a connector (not shown) to lines for infusion or withdrawal of fluids (not shown).
  • the needles are removed or the connectors are replaced with fresh, sterile protective end caps.
  • the lumens are then typically flushed with normal saline, after which a lock solution is injected into each lumen.
  • catheters for use with this invention can be prepared from a variety of materials, including, for example, silicon, polyurethane, polyvinyl, silicone, or silastic elastomer.
  • Chronic catheters are usually inserted through an internal jugular vein into the superior vena cava.
  • these catheters include a cuff attached to the exterior of the catheter and placed under the skin, which promotes ingrowth of fibrous tissue, and thus fixes the catheter in position and prevents bacterial migration around the catheter.
  • the catheters are manufactured to function for several months, for example, TESIO catheters can last for up to four years with proper intervention, in actual practice, the catheters, prior to the present invention, have exhibited limited longevity because of occlusion and/or infection. These catheters frequently must then be removed and/or replaced.
  • catheters are commonly filled with lock solutions comprising an anticoagulant agent and sometimes a second agent having antibacterial properties. It has unexpectedly been determined that citrate salt solutions as described herein exhibit surprisingly effective antibacterial activity. In a series of tests, with a variety of bacterium spores injected into a 47% solution of citrate salts, a six-log kill is obtained in seven days for E.coli and P.aeruginosa, and in 21 days for S.Aureus.
  • a catheter lock solution comprising a citrate salt is used to increase the patency of implanted catheters.
  • the term "lock solution” refers to a solution that is injected or otherwise infused into a lumen of a catheter and with the intention of allowing a substantial portion of a lock solution to remain in the lumen until it is desired or required to access that particular lumen again, typically for additional treatment, i.e., infusion or withdrawal of fluid.
  • the lock solution can remain in the lumen for a desired amount of time lasting from about 1 hour to 3 or 4 days or longer. However, frequently the lock solution is changed on a daily basis during regular care and sterile maintenance of the indwelling catheter.
  • Use of a lock solution of the present invention provides particular advantages for patients with catheters by prolonging the lifetime of the catheter, lengthening the interval between required replacements of the lock solution and inhibiting infections in the patient.
  • the lock solution employed in the present invention is preferably, but not exclusively, a hypertonic lock solution.
  • hypertonic is used herein to refer to a fluid having an osmotic concentration and a density greater than the osmotic concentration and density of the blood of the patient.
  • the lock solution preferably comprises a citrate salt with a concentration range, in weight percent, of from 10% to 40% with an osmolality of 300 to 6400 nmol. More preferably, the lock solution comprises citrate salt in a concentration range of from 20% to 30%.
  • the lock solution is prepared to have sufficient viscosity and density to remain in the lumen for a desired amount of time.
  • catheters are manufactured to have a variety of configurations and lumen diameters.
  • catheters can include single or double lumens.
  • the double lumens can be fused adjacent to each other or they can be concentric.
  • the lumens can have varying cross-sectional areas and shapes, ranging from substantially circular to substantially ovoid.
  • a phenomenon common to most lock solutions is that a portion of the solution at the distal end of the lumen diffuses into the patient's blood stream and is replaced in the catheter by blood, While not intending to be bound by any theory, it is thought that the rate of diffusion of a lock solution from a lumen can be influenced by the cross-sectional shape and area of the particular lumen(s), the density of the lock solution, and the viscosity of the lock solution. Typically, high density lock solutions tend to fall out of the lumen of the catheter, allowing blood to enter into the lumen.
  • a lock solution used in the present invention is preferably prepared to have a viscosity and density such that a substantial portion of the lock solution does not diffuse or flow out of a catheter lumen within about 8 hours. More preferably, the lock solution of the present invention does not diffuse out of a lumen to a substantial extent within 12 hours, still more preferably within 24 hours.
  • the lock solution of the invention is prepared to have a selected density of from 1.02 g/ml to 1.04 g/ml and a viscosity of from 1.5 mPa to 4.0 mPa. More preferably the lock solution has a density of from 1.02 g/ml to 1.03 g/ml and a viscosity of from 1.5 mPa to 2.0 mPa.
  • the density of the lock solution can be varied by varying the amount of salts included in the solution, with 46.7% being appropriate for 10 French cylindrical catheters, and 23% being appropriate for the double-D shaped lumens of the SPLITCATH®.
  • the viscosity of the lock solution can be varied by adding a viscosifying agent.
  • Viscosifying agents useful with the present invention include those pharmaceutically acceptable agents known or commonly used in treatment of animals including humans. Examples include, but are not limited to, polyethylene glycol, glycerin, polygeline, and non-metabolizable sugars such as sorbitol and mannitol and mixtures of these compounds.
  • An excellent embodiment of the invention therefore is a composition useful as a lock solution that comprises a citrate salt and a viscosifying agent.
  • the viscosifying agent allows a higher concentration of citrate to be used without having egress of the lock solution from the catheter due to high density of the lock solution.
  • the lock solution is prepared to have a pH lower than that of the pH of the patient's blood.
  • the lock solution may advantageously be prepared to have a pH lower than 6.5, more preferably, the lock solution is prepared to have a pH level of from 4.5 to 6.5. Still yet more preferable, the lock solution is prepared to have a pH level of from 5.0 to 6.5. The lower the pH, the greater the antibacterial effect of the citrate and the greater the caustic activity in dissolving clots.
  • the pH of the catheter lock solution can be varied by adding either an acid or base according to methods known to those skilled in the art. For example, the pH of the catheter lock solution can be lowered by including a sufficient amount of citric acid to the solution to provide the desired pH level.
  • the lock solution can be prepared to include a variety of other pharmaceutically acceptable agents.
  • the lock solution can include salts, such as, for example, sodium chloride and sodium heparin.
  • the lock solution can also include a variety of other antibacterial, antimicrobial and anticoagulant agents.
  • antibacterial and antimicrobial agents are well known to those skilled in the art and can include, without limitation, gentamicin, vancomycin, and mixtures of these agents.
  • Additional anticoagulant agents include, for example heparin, urokinase, tissue plasminogen activation (tPA)and mixtures of these agents.
  • pharmaceutically acceptable it is meant that the lock solution and the included salts and other additives which are, within the scope of sound medical judgment, suitable for use in contact with tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with the reasonable benefit/risk ratio. It is also typically necessary that a composition be sterilized to reduce the risk of infection.
  • pharmaceutically acceptable salts are well-known in the art, for example, as found in S.M. Berge et al. described in detail in J. Pharmaceutical Science, 66:1-19, 1977.
  • the present invention provides a method of inhibiting infections in animals having an indwelling intravascular catheter.
  • a compound having anticoagulant and antibacterial activity is selected, for example, the citrate salt such as trisodium citrate.
  • a lock solution is prepared, including the compound having anticoagulant and antibacterial activity. The resulting lock solution is then infused into the lumen or a catheter.
  • the lock solution (including a citrate salt) further includes a bactericidal component.
  • the bactericidal component includes greater than 50% by weight based on the weight of the bactericidal component of the citrate salt. More preferably, the bactericidal component includes greater than about 75%, by weight based on the weight of the component, of the citrate salt. Still more preferably, the bactericidal component includes greater than about 90% of a citrate salt.
  • lock solution Once a lock solution is infused into the lumen of the catheter, it is allowed to remain until that particular catheter or lumen is desired to be accessed again.
  • the lock solution can be flushed directly into the patient without the necessity of removing the fluid before infusing fluids for subsequent treatment.
  • the lock solution can be removed from the catheter prior to infusion or removal of additional fluid for further treatment.
  • a sufficient amount of the lock solution can be injected to substantially fill the lumen of the catheter.
  • a volume less than the amount of fluid needed to fill the catheter can be injected into the lumen.
  • a sufficient amount of lock solution can be injected into the catheter to fill 80 to 100% of the internal volume of the catheter.
  • an amount greater than the internal volume of the catheter can be injected.
  • an amount of the lock solution greater than or equal to about 1.1 times the internal volume of the catheter can be injected into the lumen, without adverse effects on the clotting system of the patient.
  • the lock solution can be infused into the lumen or lumens of the indwelling catheter of patients exhibiting a risk of infection.
  • Surgically implanted catheters are used in the treatment of patients exhibiting a variety of health problems. It is well known that certain health problems and/or patients exhibit increased risk of infection based upon historical observation by those skilled in the art.
  • the present invention provides distinct advantages when used on those patients having an increased risk of infection by inhibiting infection in those patients.
  • a catheter lock solution prepared according to the present invention is infused into the lumen of the catheter.
  • the catheter lock includes a citrate salt in a concentration effective to eliminate the infection and/or reduce the likelihood of subsequent infection.
  • a lock solution as employed in the present invention has other advantages besides antibacterial properties. If infused into a patient, citrate in the lock solution will be inactivated by calcium in the blood or calcium derived from body stores. When a lock solution having a hypertonic citrate concentration of 47% is used, the total amount of citrate in the lock solution contained in one lumen of a tunneled catheter is approximately 2 ml, containing 3.4 mM of sodium citrate. This amount of citrate is equal to the amount of calcium contained in 1.5 liters of blood. If infused rapidly, this amount of citrate could cause transient hypocalcemic symptoms, but would not anticoagulate the patient. Therefore, if a tunneled catheter is used for fluid infusion for a patient in the emergency room or operating room, the patient will not become anticoagulated just at the time when blood coagulation is important.
  • a study utilizing concentrated citrate in the catheter lock solution was performed on an outpatient dialysis unit (RTC) with 60% of patients having chronic central venous catheters (50 catheters total, the majority ASH SPILTCATH® and the remaining TESIO® and HICKMAN® catheters).
  • RTC outpatient dialysis unit
  • the citrate concentration in the lock solution was increased from 10% to 20% to 47%.
  • Gentamicin was added at 3 mg/ml to the 10% and the 20% solutions, but not to the 47% citrate solution.
  • the overall incidence of bacteremia in the unit was followed and the amount of urokinase used to open occluded or low-flowing catheters was recorded. The results were compared in incidences of bacteremia and use of urokinase in the unit before the implementation of the lock solution containing citrate salts.
  • the average monthly incidence of positive blood cultures in the unit was calculated for the time period from January 1998 through July 1998.
  • heparin was used as the standard catheter lock solution, with either 5,000 units or 10,000 units instilled into each lumen at exactly the catheter volume.
  • the incidence of bacteremia during this period was 4.6%, which was higher than the average level since 1994.
  • hemodialysis patients were informed of the plan to change from heparin to sodium citrate/gentamicin as the standard anticoagulant lock for tunneled catheters. From September to December 1998, 10% citrate with 3 mg/ml gentamicin was used as standard catheter lock, injecting slightly more than the catheter volume (2.5 ml total).
  • the unit use of urokinase (Abbott Laboratories) was monitored.
  • the number of vials of urokinase use by the RTC unit was calculated on a monthly basis.
  • the total number of vials ordered and used by the unit each month in the period from January 1998 through July 1998 was compared to the number of vials used after the conversion to citrate, from September 1998 to July 1999. After May 1999, urokinase became unavailable, but before this time it was available on request.
  • the number of vials used per month in the baseline period was compared to the number of vials after implementation of citrate/gentamicin or 47% citrate catheter lock, by Two-tailed T Test (assuming equal variances).
  • the outpatient unit has many patients with tunneled catheters, nurses and technicians use utmost care in opening the catheters and connecting to dialysis machines.
  • the caps of the catheter are soaked in betadine for 5 minutes before the caps are removed. Nurses and technicians wear masks and gloves, and the patient wears a mask when the catheter is opened. New protective caps are placed on the catheter following each procedure. Catheters and connectors are inspected for leaks or evidence of damage, each treatment.
  • urokinase in the dialysis unit during the baseline period was 41 vials per month, or approximately 1 vial per patient with tunneled catheter per month.
  • tPA tissue plasminogen activator
  • hypertonic citrate (10 or 20%) in combination with gentamicin, or 47% citrate are at least as effective as heparin in preventing clotting of the catheters.
  • the use of urokinase to open these tunneled catheters does not increase, and in fact significantly decreases after implementation of the citrate catheter lock solutions.
  • Hypertonic citrate as catheter lock appears to decrease the incidence of bacteremia in a dialysis unit with a high percentage of patients with tunneled catheters.
  • citrate containing 3 mg/ml gentamicin
  • An even greater decrease in incidence of bacteremia appears to occur with use of 47% citrate alone (without gentamicin).
  • concentrated citrate is bactericidal and sporicidal when tested in vitro. Therefore, it is expected that it would diminish the bacterial content of catheters after chance contamination of the catheter hub.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)

Claims (13)

  1. Utilisation d'une solution de sel citrate ayant une concentration pour éliminer une infection et réduire la probabilité d'une infection subséquente pour la fabrication d'un médicament sous la forme d'une solution de remplissage de cathéter à infuser dans la lumière d'un cathéter intravasculaire à demeure d'un patient ayant une infection ou un risque substantiel d'infection liée à la présence du cathéter, dans laquelle la solution de remplissage comprend le sel citrate en une gamme de concentration, en pourcentage en poids, entre 10% et 50%.
  2. Utilisation selon la revendication 1, dans laquelle la solution de remplissage inclut un agent conférant de la viscosité choisi parmi un polyéthylèneglycol, la glycérine, une polygéline et des mélanges de ceux-ci.
  3. Utilisation selon la revendication 1 ou 2, dans laquelle la solution de remplissage a un niveau de pH entre 4,5 et 6,5.
  4. Utilisation selon l'une quelconque des revendications 1 à 3, dans laquelle la solution de remplissage a une masse volumique de 1,02g/ml à 1,04g/ml et une viscosité entre 1,5 mPA et 4,0 mPa.
  5. Utilisation d'un constituant bactéricide incluant plus de 50% en poids, sur la base du poids du constituant bactéricide, d'un sel citrate pour la fabrication d'un médicament sous la forme d'une solution de remplissage de cathéter pharmaceutiquement acceptable à infuser dans la lumière d'un cathéter intravasculaire à demeure qui a été implanté chirurgicalement dans un animal ayant une infection ou risque substantiel d'infection liée à la présence du cathéter.
  6. Utilisation selon la revendication 5, dans laquelle le constituant bactéricide inclut plus de 75% en poids, sur la base du poids du constituant bactéricide, du sel citrate.
  7. Utilisation selon la revendication 5 ou 6, dans laquelle le constituant bactéricide inclut plus de 90% en poids, sur la base du poids du constituant bactéricide, du sel citrate.
  8. Utilisation selon l'une quelconque des revendications 5 à 7, dans laquelle la solution de remplissage inclut un agent conférant de la viscosité.
  9. Utilisation selon l'une quelconque des revendications 5 à 8, dans laquelle la solution de remplissage pharmaceutiquement acceptable a un pH entre 4,5 et 6,5.
  10. Utilisation selon la revendication 5, dans laquelle la solution de remplissage comprend le sel citrate en une gamme de concentration, en pourcentage en poids, entre 1,5% et 50%.
  11. Utilisation selon la revendication 10, dans laquelle la solution de remplissage comprend le sel citrate en une gamme de concentration, en pourcentage en poids, entre 10% et 50%.
  12. Utilisation selon l'une quelconque des revendications 1 à 11, dans laquelle ledit sel citrate comprend un sel citrate de sodium.
  13. Utilisation selon l'une quelconque des revendications 1 à 12, dans laquelle ladite solution de remplissage inclut du citrate en tant qu'unique agent antibactérien.
EP99943881A 1998-08-25 1999-08-25 Utilisation de citrate dans une solution de controle de catheter Revoked EP1107807B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9777798P 1998-08-25 1998-08-25
US97777P 1998-08-25
PCT/US1999/019307 WO2000010385A1 (fr) 1998-08-25 1999-08-25 Procede d'augmentation de permeabilite de catheter a l'aide d'une solution de rincage a base de citrate

Publications (3)

Publication Number Publication Date
EP1107807A1 EP1107807A1 (fr) 2001-06-20
EP1107807A4 EP1107807A4 (fr) 2003-10-01
EP1107807B1 true EP1107807B1 (fr) 2006-10-11

Family

ID=22265079

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99943881A Revoked EP1107807B1 (fr) 1998-08-25 1999-08-25 Utilisation de citrate dans une solution de controle de catheter

Country Status (9)

Country Link
EP (1) EP1107807B1 (fr)
JP (1) JP2002523336A (fr)
AT (1) ATE342103T1 (fr)
AU (1) AU5689199A (fr)
DE (1) DE69933572T2 (fr)
DK (1) DK1107807T3 (fr)
ES (1) ES2275352T3 (fr)
PT (1) PT1107807E (fr)
WO (1) WO2000010385A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248093B2 (en) 2009-06-11 2016-02-02 Becton, Dickinson And Company Catheter locking solution having antimicrobial and anticoagulation properties

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6685694B2 (en) * 1999-07-23 2004-02-03 Vasca, Inc. Methods and kits for locking and disinfecting implanted catheters
US6497676B1 (en) 2000-02-10 2002-12-24 Baxter International Method and apparatus for monitoring and controlling peritoneal dialysis therapy
DE60133893D1 (de) * 2000-05-10 2008-06-19 Ash Access Technology Inc Kathetersperrlösung mit photo-oxidant
ATE428464T1 (de) * 2000-07-07 2009-05-15 Excelsior Medical Corp Vorrichtung und kits zum feststellen und desinfizieren eingesetzter katheter
JP2006008696A (ja) * 2003-03-20 2006-01-12 Mitsubishi Pharma Corp アルギニンアミド類を含有する医薬製剤
US7696182B2 (en) * 2004-11-02 2010-04-13 Nd Partners, Llc Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
US7749529B2 (en) 2005-02-08 2010-07-06 Ash Access Technology, Inc. Catheter lock solution comprising citrate and a paraben
JP5417691B2 (ja) * 2007-07-19 2014-02-19 株式会社ジェイ・エム・エス 弱酸を含有する血管内留置カテーテルのロック溶液
JP5194956B2 (ja) * 2008-03-31 2013-05-08 株式会社ジェイ・エム・エス 酸性ヘパリン水溶液を調製し、保存するための容器、および酸性ヘパリン水溶液の調製方法
WO2010064324A1 (fr) 2008-12-05 2010-06-10 株式会社ジェイ・エム・エス Solution de rinçage pour cathéter intravasculaire à demeure contenant de l'acide acétique et récipient contenant cette solution
WO2010088192A1 (fr) 2009-01-27 2010-08-05 Telelflex Medical Incorporated Composition bactériostatique de blocage de cathéter contenant du glycérol
US8691286B2 (en) * 2009-01-27 2014-04-08 Teleflex Medical Incorporated Sputum dissolving suctioning solution for endotracheal and tracheostomy tubes
JP5412857B2 (ja) * 2009-02-03 2014-02-12 株式会社ジェイ・エム・エス 静菌効果を有するカテーテルロック液と該カテーテルロック液の調製方法
CN102724872B (zh) 2009-11-24 2017-06-09 弗雷森纽斯医疗护理德国有限责任公司 消毒剂组合物
DE202010006267U1 (de) * 2010-04-23 2010-11-11 Anbatec Gmbh Produkt mit einer antimikrobiell wirksamen Oberfläche
US8951577B2 (en) 2010-08-03 2015-02-10 Teleflex Medical Incorporated Antimicrobial hydrochloric acid catheter lock solution and method of use
GB2502291A (en) * 2012-05-21 2013-11-27 Andrew Breakell A urinary catheter cleaning device using lock fluid
US10517892B2 (en) 2013-10-22 2019-12-31 Medtronic Minimed, Inc. Methods and systems for inhibiting foreign-body responses in diabetic patients
JP2014024870A (ja) * 2013-11-06 2014-02-06 Jms Co Ltd 静菌効果を有するカテーテルロック液と該カテーテルロック液の調製方法
RU2734929C2 (ru) * 2016-02-12 2020-10-26 Медикал Компонентс, Инк. Раствор замка катетера и терапия с применением замка катетера
US11179516B2 (en) 2017-06-22 2021-11-23 Baxter International Inc. Systems and methods for incorporating patient pressure into medical fluid delivery
JP7138702B2 (ja) 2017-09-22 2022-09-16 ベクトン・ディキンソン・アンド・カンパニー カテーテルロック溶液としての使用のための４％クエン酸三ナトリウム溶液
KR101989054B1 (ko) * 2017-11-28 2019-06-13 (주)다림티센 지혈용 조성물 및 이를 포함하는 용기
US11738120B1 (en) 2022-04-14 2023-08-29 Cormedix Inc. Synthesis of taurolidine, purity profiles and polymorphs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364929A (en) * 1979-04-02 1982-12-21 The Purdue Frederick Company Germicidal colloidal lubricating gels and method of producing the same
US4677143A (en) * 1984-10-01 1987-06-30 Baxter Travenol Laboratories, Inc. Antimicrobial compositions
DK708488D0 (da) * 1988-12-20 1988-12-20 Nordisk Gentofte Faktor i praeparat
US5688516A (en) * 1992-11-12 1997-11-18 Board Of Regents, The University Of Texas System Non-glycopeptide antimicrobial agents in combination with an anticoagulant, an antithrombotic or a chelating agent, and their uses in, for example, the preparation of medical devices
US5843016A (en) * 1996-03-18 1998-12-01 Physion S.R.L. Electromotive drug administration for treatment of acute urinary outflow obstruction

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248093B2 (en) 2009-06-11 2016-02-02 Becton, Dickinson And Company Catheter locking solution having antimicrobial and anticoagulation properties
US9744273B2 (en) 2009-06-11 2017-08-29 Becton, Dickson And Company Catheter locking solution having antimicrobial and anticoagulation properties

Also Published As

Publication number Publication date
DE69933572T2 (de) 2007-06-28
ES2275352T3 (es) 2007-06-01
EP1107807A4 (fr) 2003-10-01
ATE342103T1 (de) 2006-11-15
JP2002523336A (ja) 2002-07-30
PT1107807E (pt) 2007-01-31
DE69933572D1 (de) 2006-11-23
DK1107807T3 (da) 2007-02-19
WO2000010385A1 (fr) 2000-03-02
EP1107807A1 (fr) 2001-06-20
AU5689199A (en) 2000-03-14

Similar Documents

Publication Publication Date Title
US6958049B1 (en) Method of enhancing catheter patency using a citrate salt catheter lock solution
EP1107807B1 (fr) Utilisation de citrate dans une solution de controle de catheter
US20050215978A1 (en) Method of enhancing catheter patency using a citrate salt catheter lock solution
AU2006212946B2 (en) A catheter lock solution comprising citrate and a paraben
EP1442753B1 (fr) Composition pour la prévention des infections par prothèses endovasculaires
Swartz et al. Successful use of cuffed central venous hemodialysis catheters inserted percutaneously.
JP2006232829A5 (fr)
US20100010086A1 (en) Antimicrobial therapy for indwelling catheters and for sanitizing surfaces
EP1284780B1 (fr) Solution de controle de sonde contenant un photo-oxydant
Canaud et al. Dialock: pilot trial of a new vascular port access device for hemodialysis
Ronco et al. Vascular access for continuous renal replacement therapy
TW201323024A (zh) 皮膚穿透靜脈接觸鎖定溶液

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010323

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20030812

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ASH ACCESS TECHNOLOGY, INC.

17Q First examination report despatched

Effective date: 20040705

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/194 20060101ALI20060316BHEP

Ipc: A61P 31/04 20060101AFI20060316BHEP

RTI1 Title (correction)

Free format text: USE OF CITRATE IN A CATHETER LOCK SOLUTION

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69933572

Country of ref document: DE

Date of ref document: 20061123

Kind code of ref document: P

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20070108

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: RITSCHER & PARTNER AG

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2275352

Country of ref document: ES

Kind code of ref document: T3

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: DIRINCO B.V.

Effective date: 20070711

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

NLR1 Nl: opposition has been filed with the epo

Opponent name: DIRINCO B.V.

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: RITSCHER & PARTNER AG;RESIRAIN 1;8125 ZOLLIKERBERG (CH)

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20070112

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061011

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100825

PGRI Patent reinstated in contracting state [announced from national office to epo]

Ref country code: IT

Effective date: 20110616

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20110825

Year of fee payment: 13

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20110810

Year of fee payment: 13

Ref country code: MC

Payment date: 20110726

Year of fee payment: 13

Ref country code: CH

Payment date: 20110812

Year of fee payment: 13

Ref country code: IE

Payment date: 20110810

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20110817

Year of fee payment: 13

Ref country code: FI

Payment date: 20110810

Year of fee payment: 13

Ref country code: ES

Payment date: 20110915

Year of fee payment: 13

Ref country code: FR

Payment date: 20110818

Year of fee payment: 13

Ref country code: AT

Payment date: 20110726

Year of fee payment: 13

Ref country code: SE

Payment date: 20110811

Year of fee payment: 13

Ref country code: GB

Payment date: 20110824

Year of fee payment: 13

Ref country code: PT

Payment date: 20110825

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20110810

Year of fee payment: 13

Ref country code: BE

Payment date: 20110812

Year of fee payment: 13

Ref country code: NL

Payment date: 20110818

Year of fee payment: 13

BERE Be: lapsed

Owner name: ASH ACCESS TECHNOLOGY, INC.

Effective date: 20120831

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20130225

REG Reference to a national code

Ref country code: NL

Ref legal event code: V1

Effective date: 20130301

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120831

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 342103

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120825

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20120825

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120825

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120831

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120826

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120831

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130301

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20130430

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130225

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120831

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120825

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120825

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120825

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120831

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120825

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120831

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69933572

Country of ref document: DE

Effective date: 20130301

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20131022

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

27W Patent revoked

Effective date: 20111018

REG Reference to a national code

Ref country code: AT

Ref legal event code: MA03

Ref document number: 342103

Country of ref document: AT

Kind code of ref document: T

Effective date: 20111018

REG Reference to a national code

Ref country code: SE

Ref legal event code: ECNC